** Shares of drug developer Moleculin Biotech MBRX.O rise 488% to $2.44; set to record their largest single-day percentage gain
** MBRX says U.S. FDA has approved company's plan for a late-stage trial to test its drug, annamycin, a potential treatment for acute myeloid leukemia, a type of blood and bone marrow cancer
** Says FDA recommended a reduction in the size of the trial by about 10% due to an alteration in the statistical plan
** Annamycin received "fast track" and "orphan drug" designation from the FDA
** MBRX fell 87.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。